Sanofi: positive results in myeloma trial
(CercleFinance.com) - Sanofi announces that the isatuximab phase III trial has met its primary endpoint for the extension of progression-free survival in patients with multiple recurrent/refractory myeloma.
This study, called ICARIA-MM, recruited 307 patients in 96 clinical centres in 24 different countries. It focused on the second hematologic cancer in terms of frequency, with over 138,000 new cases each year in the world.
The results of this test will be communicated at a forthcoming medical conference and should be made available for submission to regulatory authorities in the course of the year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
This study, called ICARIA-MM, recruited 307 patients in 96 clinical centres in 24 different countries. It focused on the second hematologic cancer in terms of frequency, with over 138,000 new cases each year in the world.
The results of this test will be communicated at a forthcoming medical conference and should be made available for submission to regulatory authorities in the course of the year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.